AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.

In a recent large-scale code modernization initiative, a team used generative AI to convert a clinical data standards library from one programming language to another. Nearly 80% of the templates transitioned automatically, compressing what would have been months of manual effort into a fraction of the time. Yet the remaining third, platform-specific functions, nuanced derivations, and intricate data transformations, still required deep human expertise to refine and validate. The real story is the shift in ownership.

The Split Is Already Happening

That split is already reshaping the field. Over the next five years, statistical programmers will sort themselves into two camps: those who learn to direct AI tools toward regulatory-grade output, and those who continue writing every line by hand. Both groups will still have jobs. But the first group will work on more studies, take on higher-complexity problems, and move into leadership roles faster. The second group will find their scope shrinking as sponsors expect more output per programmer per quarter.

During a major NDA submission, our programming team spent over two weeks developing SDTM specifications under intense time pressure. We didn’t use AI during that project, but going through that manual grind made one thing clear: specification generation should not be a bottleneck. That experience led me to develop the AI-powered Automated Spec Creator on ClinStandards.org, a tool that generates draft specifications directly from code to eliminate those delays.

The second inflection point came as I observed the industry shifting toward programming language–agnostic data standardization. As organizations increasingly moved between SAS, R, and Python, the need for seamless translation became evident. In response, I built an AI-driven Code Converter tool that allows programmers to translate their own code across languages, accelerating learning while preserving domain logic.

Building those tools taught me where AI adds speed and where it introduces risk. That distinction matters more in clinical programming than in any other corner of software development.

Where AI Breaks in a GxP Environment

The phrase people keep using is 'vibe coding', which is writing software by describing what you want rather than typing every instruction. In a typical software shop, that works because you can ship fast and fix bugs later. Clinical programming doesn't have that luxury. Every dataset that reaches a regulatory agency carries validation requirements. You cannot vibe your way through a metadata file that a reviewer will trace line by line back to your source data.

But you can vibe your way through the scaffolding. AI-generated code handles repetitive data manipulation, straightforward mapping tasks, and boilerplate structures well. At PharmaSUG 2025, multiple presentations confirmed this pattern. One recap from Catalyst Clinical Research noted a speaker who compared generative AI to a capable intern: useful for starting tasks, but requiring human oversight for anything that touches validation or accountability. Where AI struggles most is in statistical derivations that carry regulatory weight (survival calculations, response criteria, subgroup safety logic.) These require a programmer who understands the clinical context behind every conditional statement, not just the syntax.

I saw this during an independent evaluation of generative AI tools. I tasked an AI with generating a Define-XML structure for a simulated PMDA submission. At first glance, the output looked polished. It wasn’t. The model had hallucinated; schema inconsistencies, entirely fabricated elements that defied regulatory specifications. If a team had trusted and submitted that output in a real-world scenario, the submission would have been rejected on technical grounds alone.

The FDA Is Making Room

The FDA's own trajectory creates more room for AI-assisted workflows, not less. In January 2025, the agency released its first draft guidance on AI in drug development, proposing a risk-based credibility framework for evaluating AI model outputs. The agency had reviewed more than 500 drug submissions with AI components between 2016 and 2023, and that number is climbing. Separately, the FDA is exploring CDISC Dataset-JSON v1.1 as a potential replacement for the legacy SAS V5 XPT transport format, which has been the submission standard since 1999. Dataset-JSON supports richer metadata and links directly to Define-XML, which means the agency is moving toward an ecosystem where traceability is built into the data exchange format itself. Programmers who can build AI-assisted pipelines that generate audit-ready metadata will have a structural advantage over those doing it manually.

Dataset-JSON is schema-driven, text-based, and machine-readable by design. That makes it a natural fit for AI-assisted validation: automated consistency checks, terminology conformance review, and traceability verification across submission layers. For programmers, the preparation is straightforward: learn the schema at a technical level and start integrating AI into controlled validation pipelines as a pre-submission safeguard, not a replacement for expertise.

SGS and SAS announced a collaboration in November 2025 to build an AI-powered agent specifically for code validation in clinical data analysis. The agent uses large language models to conduct initial code reviews, identify programming mistakes, and pre-emptively correct issues against the Statistical Analysis Plan. They are also developing automation for generating define.xml files. This is the direction of the industry: AI embedded in the validation layer, not replacing it.

Early in my career, statistical programming in clinical research meant SAS and only SAS. Today, R and Python have broadened the field and brought talented open-source developers into direct competition. Having worked across all three languages and built tools that bridge them, I keep coming back to the same conclusion: the programmers who treat AI as a collaborator rather than a threat will be the ones shaping this field five years from now. Your statistical foundation already puts you closer to the forefront of artificial intelligence than you think.

Topic: AI in Bio